Charles J L la Porte

Summary

Affiliation: Ottawa Health Research Institute
Country: Canada

Publications

  1. ncbi The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir
    C J L la Porte
    Division of Infectious Diseases, The Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada
    Clin Pharmacol Ther 82:389-95. 2007
  2. ncbi Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers
    Charles J L la Porte
    Division of Infectious Diseases, Ottawa Hospital and Ottawa Health Research Institute, University of Ottawa, Ottawa, Canada
    Antimicrob Agents Chemother 53:162-73. 2009
  3. ncbi Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children
    Charles la Porte
    Ottawa Health Research Institute, Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
    Antivir Ther 14:603-6. 2009
  4. ncbi Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers
    C J L la Porte
    Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario K1H 8L6, Canada
    Antimicrob Agents Chemother 53:4840-4. 2009
  5. ncbi Saquinavir, the pioneer antiretroviral protease inhibitor
    Charles J L la Porte
    University of Ottawa, Ottawa Hospital Research Institute, Chronic Disease Program, Department of Medicine, 501 Smyth Road, mailbox 223, Ottawa, ON, K1H 8L6, Canada
    Expert Opin Drug Metab Toxicol 5:1313-22. 2009
  6. ncbi Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects
    Charles la Porte
    Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada
    Clin Pharmacokinet 49:449-54. 2010

Detail Information

Publications6

  1. ncbi The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir
    C J L la Porte
    Division of Infectious Diseases, The Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada
    Clin Pharmacol Ther 82:389-95. 2007
    ..In conclusion, ABCB1 polymorphism has no pronounced effect on saquinavir exposure...
  2. ncbi Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers
    Charles J L la Porte
    Division of Infectious Diseases, Ottawa Hospital and Ottawa Health Research Institute, University of Ottawa, Ottawa, Canada
    Antimicrob Agents Chemother 53:162-73. 2009
    ..Combining TPV/r with RFB should be done with caution, while toxicity and RFB drug levels should be monitored. Study medications were generally well-tolerated in these studies...
  3. ncbi Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children
    Charles la Porte
    Ottawa Health Research Institute, Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
    Antivir Ther 14:603-6. 2009
    ..Once-daily lopinavir/ritonavir (LPV/r) is not approved for treatment of HIV paediatric patients. Once daily treatment in children might serve the same goals of patient comfort and adherence as in adults...
  4. ncbi Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers
    C J L la Porte
    Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario K1H 8L6, Canada
    Antimicrob Agents Chemother 53:4840-4. 2009
    ..EFV had no effect on the steady-state PK of TPV or RTV, with the exception of a 19% increase in the TPV C(min), which is not clinically relevant. TPV/r can be safely coadministered with EFV and without the need for a dose adjustment...
  5. ncbi Saquinavir, the pioneer antiretroviral protease inhibitor
    Charles J L la Porte
    University of Ottawa, Ottawa Hospital Research Institute, Chronic Disease Program, Department of Medicine, 501 Smyth Road, mailbox 223, Ottawa, ON, K1H 8L6, Canada
    Expert Opin Drug Metab Toxicol 5:1313-22. 2009
    ..This drug made the use of combination therapy in the treatment of HIV possible and increased the success rate of treatment...
  6. ncbi Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects
    Charles la Porte
    Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada
    Clin Pharmacokinet 49:449-54. 2010
    ..The present study aimed to investigate the steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol)...